> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA-483 Issued to JCB Laboratories
- URL: https://www.fdaweb.com/fda-483-issued-to-jcb-laboratories/
- Published: 2018-12-03T12:00:00.000Z
- Updated: 2026-09-15T00:48:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142939

FDA has posted a [Form FDA-483](https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-orgs/documents/document/ucm626326.pdf?ref=fdaweb.com) citing JCB Laboratories (Wichita, KS) over GMP deficiencies at the drug outsourcing operation. For example, the inspection form said there is no testing to assure that a drug product meets applicable standards of identity, strength, quality, and purity at the time of use. Also, there are no written testing programs designed to assess the stability characteristics of its drug products.